http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1343595-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e108a9172a690a28ce3ee03834e39f35 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567 |
| filingDate | 1972-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1974-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1343595-A |
| titleOfInvention | Oral contraceptive combination |
| abstract | 1343595 Oral contraceptives BIOLOGICAL CONCEPTS INC 12 Sept 1972 [22 Feb 1972] 42242/72 Heading A5B A pharmaceutical preparation for the control of the ovulatory cycle in women and adapted for oral administration, in the form of a unit dose, comprises a combination of substantially 1 part by weight of an estrogenic substance and in the range of 7 to 14 parts by weight of a progestational substance, the amount of estrogenic substance present, expressed as ethynol estradiol or the estrogenic equivalent thereof, being in the range of 0.02 to 0.045 mg per unit dose. The preferred progestational substance is norethindrone. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2192542-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2192542-A |
| priorityDate | 1972-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.